Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 04, 2015 7:14 AM ET


Company Overview of Histogen, Inc.

Company Overview

Histogen, Inc. researches, develops, manufactures, and sells regenerative medicine. It offers ExCeltrix, an insoluble extracellular matrix for therapeutic applications, which include use of dermal filler for soft tissue augmentation, bone filler for bone stimulation and critical defect repair, tissue regeneration patches for surgical applications, and coatings for devices in the areas of cardiovascular, orthopedics, and urological repair. The company also provides cell conditioned media; and hair stimulating complex, a liquid formula created by the culturing of newborn cells in a simulated embryonic environment of suspension and very low oxygen, and then harvesting the naturally secreted gro...

10655 Sorrento Valley Road

San Diego, CA 92121

United States

Founded in 2007





Key Executives for Histogen, Inc.

Founder, Chairman and Chief Executive Officer
Age: 58
President and Chief Financial Officer
Age: 60
Director of Corporate Communications
Director of Engineering
Director of Clinical Affairs
Compensation as of Fiscal Year 2014.

Histogen, Inc. Key Developments

Histogen, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Histogen, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

Histogen, Inc. Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 10:15 AM

Histogen, Inc. Presents at Stem Cell Meeting on the Mesa Partnering Forum, Oct-07-2014 10:15 AM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States.

Histogen Inc. Partners with Southern California Medical Device Group Wylde, LLC to Create Histogen Oncology

Histogen Inc. has partnered with Wylde, LLC to create Histogen Oncology. This joint venture will focus on the development of unique cell-derived materials for cancer applications. Under this joint venture, Histogen Oncology has acquired exclusive rights to Histogen's human multipotent cell conditioned media (CCM) and extracellular matrix (ECM) materials, as well as their derivatives, for oncology applications throughout North America. Histogen Oncology's initial clinical focus is pancreatic cancer, a highly treatment-resistant cancer in which a sub-fraction of the CCM has shown substantial preclinical promise. There are so many patients out there who are not candidates for existing therapies due to the toxic nature of available drugs. This is particularly true in pancreatic cancer, where 80% of people diagnosed already have stage four disease. In post-resection nude mouse models, intravenous treatment with the CCM sub-fraction resulted in prolonged survival by more than three fold in a majority of treated animals. In non-resection models, more than 50% of treated mice lived twice as long as the control. These results point to a potentially significant outcome for pancreatic cancer patients, and Histogen Oncology intends to progress the material toward a Phase I clinicaltrial for no-option pancreatic cancer patients in the coming 18 months. Research on the mechanism responsible for cancer cell inhibition by the CCM shows the upregulation of Caspase 9 and cleaved Caspase 3, which causes cancer cells to enter apoptosis, or programmed cell death. Histogen Oncology will be supported by Histogen's research group and funded by Wylde, LLC. made up of experts from the surgery and medical device industries. The creation of this joint venture allows for dedicated development of the CCM sub-fraction as a cancer treatment, as Histogen continues to allocate resources to the company's revenue-generating aesthetic and promising therapeutic programs.

Similar Private Companies By Industry

Company Name Region
NOD Pharmaceuticals, Inc. United States
GeneXP Biosciences Inc. United States
Virun, Inc. United States
MG Biotherapeutics LLC United States
Luna Analytics United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Histogen, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at